{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:34:40Z","timestamp":1794566080849,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NF2 BioSolutions UK and Europe"},{"name":"Skull Base Foundation"},{"name":"National Institute for Health and Care Research, Manchester Biomedical Research Centre"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Council, United Kingdom"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Currently there are no therapeutic agents that are effective against both vestibular schwannoma and meningioma, the two most common tumour types affecting patients with the rare tumour predisposition syndrome\n                    <jats:italic>NF2<\/jats:italic>\n                    -related schwannomatosis. This study aimed to characterise the similarities and differences in the tumour immune microenvironments of meningioma and vestibular schwannoma to identify potential therapeutic targets viable for both tumour types. Publicly available bulk Affymetrix expression data for both meningioma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922) and vestibular schwannoma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) were used to compare gene expression and signalling pathways, and deconvolved to predict the abundance of the immune cell types present. Publicly available single cell RNA sequencing data for both meningioma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) and vestibular schwannoma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915) was used to further investigate specific T cell and macrophage subtypes for their signalling pathways, gene expression, and drug targets for predicted drug repurposing in both tumour types. Immune cells comprised a larger proportion of the vestibular schwannoma tumour microenvironment compared to meningioma and included a significantly higher abundance of alternatively activated macrophages. However, these alternatively activated macrophages, alongside other immune cell subtypes such as CD8\u2009+\u2009T cells and classically activated macrophages, were predicted to be more active in meningioma than vestibular schwannoma. Despite these differences, T cells and tumour associated macrophages of both vestibular schwannoma and meningioma shared drug-target kinases amenable to drug repurposing with Food and Drug Administration (FDA) drugs approved for other conditions. These include bosutinib, sorafenib, mitoxantrone, and nintedanib which are yet to be clinically investigated for vestibular schwannoma or meningioma. Drug repurposing may offer an expedited route to the clinical translation of approved drugs effective for treating both meningioma and vestibular schwannoma to benefit\n                    <jats:italic>NF2<\/jats:italic>\n                    -related schwannomatosis patients.\n                  <\/jats:p>","DOI":"10.1186\/s40478-025-02176-9","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:16:12Z","timestamp":1766499372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis"],"prefix":"10.1186","volume":"13","author":[{"given":"Grace E.","family":"Gregory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Haley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Paul","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A. H.","family":"Zeef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Paszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Couper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar N.","family":"Pathmanaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/jnnp-2018-319713","volume":"90","author":"S Ammoun","year":"2019","unstructured":"Ammoun S, Evans DG, Hilton DA, Streeter A, Hayward C, Hanemann CO (2019) Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. J Neurol Neurosurg Psychiatry 90:1184\u20131187. https:\/\/doi.org\/10.1136\/jnnp-2018-319713","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3171\/jns.1997.87.4.0610","volume":"87","author":"J Antinheimo","year":"1997","unstructured":"Antinheimo J, Haapasalo H, Haltia M, Tatagiba M, Thomas S, Brandis A, Sainio M, Carpen O, Samii M, J\u00e4\u00e4skel\u00e4inen J (1997) Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 87:610\u2013614. https:\/\/doi.org\/10.3171\/jns.1997.87.4.0610","journal-title":"J Neurosurg"},{"key":"2176_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbac016","author":"P Badia-i-Mompel","year":"2022","unstructured":"Badia-i-Mompel P, V\u00e9lez Santiago J, Braunger J, Geiss C, Dimitrov D, M\u00fcller-Dott S, Taus P, Dugourd A, Holland CH, Ramirez Flores RO, Saez-Rodriguez J (2022) decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform Adv. https:\/\/doi.org\/10.1093\/bioadv\/vbac016","journal-title":"Bioinform Adv"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41467-023-42762-w","volume":"15","author":"TF Barrett","year":"2024","unstructured":"Barrett TF, Patel B, Khan SM, Mullins RDZ, Yim AKY, Pugazenthi S, Mahlokozera T, Zipfel GJ, Herzog JA, Chicoine MR, Wick CC, Durakovic N, Osbun JW, Shew M, Sweeney AD, Patel AJ, Buchman CA, Petti AA, Puram SV, Kim AH (2024) Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state. Nat Commun 15:478. https:\/\/doi.org\/10.1038\/s41467-023-42762-w","journal-title":"Nat Commun"},{"key":"2176_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/J.2517-6161.1995.TB02031.X","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289\u2013300. https:\/\/doi.org\/10.1111\/J.2517-6161.1995.TB02031.X","journal-title":"J R Stat Soc Ser B"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/neuonc\/nor072","volume":"13","author":"ML Bush","year":"2011","unstructured":"Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen C-S, Chang L-S, Welling DB, Jacob A (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 13:983\u2013999. https:\/\/doi.org\/10.1093\/neuonc\/nor072","journal-title":"Neuro Oncol"},{"key":"2176_CR7","unstructured":"Carvalho B (2015) pd.hugene.1.0.st.v1: Platform Design Info for Affymetrix HuGene-1_0-st-v1. R package version 3.14.1. Bioconductor"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12","journal-title":"Methods Mol Biol"},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1038\/s41598-017-05769-0","volume":"7","author":"H Chen","year":"2017","unstructured":"Chen H, Xue L, Wang H, Wang Z, Wu H (2017) Differential NF2 gene status in sporadic vestibular schwannomas and its prognostic impact on tumour growth patterns. Sci Rep 7:5470. https:\/\/doi.org\/10.1038\/s41598-017-05769-0","journal-title":"Sci Rep"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, Seo K, Lucas C-HG, Casey-Clyde TJ, Vasudevan HN, Liu SJ, Villanueva-Meyer JE, Lam T-C, Pu JK-S, Li L-F, Leung GK-K, Swaney DL, Zhang MY, Chan JW, Qiu Z, Martin MV, Susko MS, Braunstein SE, Bush NAO, Schulte JD, Butowski N, Sneed PK, Berger MS, Krogan NJ, Perry A, Phillips JJ, Solomon DA, Costello JF, McDermott MW, Rich JN, Raleigh DR (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649\u2013659. https:\/\/doi.org\/10.1038\/s41588-022-01061-8","journal-title":"Nat Genet"},{"key":"2176_CR11","first-page":"603","volume":"84","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603\u2013618","journal-title":"Q J Med"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/NEUONC\/NOS129","volume":"14","author":"S Goutagny","year":"2012","unstructured":"Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, Kalamarides M (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14:1090\u20131096. https:\/\/doi.org\/10.1093\/NEUONC\/NOS129","journal-title":"Neuro Oncol"},{"key":"2176_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae400","author":"GE Gregory","year":"2024","unstructured":"Gregory GE, Haley MJ, Jones AP, Hannan CJ, Evans DG, King AT, Paszek P, Pathmanaban ON, Couper KN, Brough D (2024) Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcae400","journal-title":"Brain Commun"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"i94","DOI":"10.1093\/noajnl\/vdac127","volume":"5","author":"GE Gregory","year":"2023","unstructured":"Gregory GE, Islim AI, Hannan CJ, Jones AP, Hammerbeck-Ward C, Rutherford SA, Freeman SR, Lloyd S, Kalamarides M, Smith MJ, Couper K, McBain CA, Jenkinson MD, Brough D, King AT, Evans DG, Pathmanaban ON (2023) The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis. Neuro-Oncol Adv 5:i94\u2013i104. https:\/\/doi.org\/10.1093\/noajnl\/vdac127","journal-title":"Neuro-Oncol Adv"},{"key":"2176_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad197","author":"GE Gregory","year":"2023","unstructured":"Gregory GE, Jones AP, Haley MJ, Hoyle C, Zeef LAH, Lin I-H, Coope DJ, King AT, Evans DG, Paszek P, Couper KN, Brough D, Pathmanaban ON (2023) The comparable tumour microenvironment in sporadic and NF2 -related schwannomatosis vestibular schwannoma. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcad197","journal-title":"Brain Commun"},{"key":"2176_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109287","volume":"249","author":"GE Gregory","year":"2023","unstructured":"Gregory GE, Munro KJ, Couper KN, Pathmanaban ON, Brough D (2023) The NLRP3 inflammasome as a target for sensorineural hearing loss. Clin Immunol 249:109287. https:\/\/doi.org\/10.1016\/j.clim.2023.109287","journal-title":"Clin Immunol"},{"key":"2176_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2012.01306.x","author":"C Hagel","year":"2012","unstructured":"Hagel C, Stemmer-Rachamimov AO, Bornemann A, Schuhmann M, Nagel C, Huson S, Evans DG, Plotkin S, Matthies C, Kluwe L, Mautner V-F (2012) Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology. https:\/\/doi.org\/10.1111\/j.1440-1789.2012.01306.x","journal-title":"Neuropathology"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","volume":"54","author":"D Halliday","year":"2017","unstructured":"Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, Evans DG, Parry A (2017) Genetic severity score predicts clinical phenotype in NF2. J Med Genet 54:657\u2013664. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104519","journal-title":"J Med Genet"},{"key":"2176_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa023","author":"CJ Hannan","year":"2020","unstructured":"Hannan CJ, Lewis D, O\u2019Leary C, Donofrio CA, Evans DG, Roncaroli F, Brough D, King AT, Coope D, Pathmanaban ON (2020) The inflammatory microenvironment in vestibular schwannoma. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaa023","journal-title":"Neuro-Oncol Adv"},{"key":"2176_CR20","doi-asserted-by":"crossref","unstructured":"Jones AP, Haley MJ, Gregory GE, Hannan CJ, Simmons AK, Bere LD, Lewis DG, Oliveira P, Smith MJ, King AT, Evans DGE, Paszek P, Brough D, Pathmanaban ON, Couper KN (2024) High-dimensional imaging of vestibular schwannoma reveals distinctive immunological networks across histomorphic niches in NF2-related schwannomatosis","DOI":"10.1101\/2024.04.09.588593"},{"key":"2176_CR21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","volume":"20","author":"MA Karajannis","year":"2021","unstructured":"Karajannis MA, Mauguen A, Maloku E, Xu Q, Dunbar EM, Plotkin SR, Yaffee A, Wang S, Roland JT, Sen C, Placantonakis DG, Golfinos JG, Allen JC, Vitanza NA, Chiriboga LA, Schneider RJ, Deng J, Neubert TA, Goldberg JD, Zagzag D, Giancotti FG, Blakeley JO (2021) Phase 0 clinical trial of Everolimus in patients with vestibular schwannoma or meningioma. Mol Cancer Ther 20:1584\u20131591. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0143","journal-title":"Mol Cancer Ther"},{"key":"2176_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","volume":"57","author":"L Kn\u00fcppel","year":"2017","unstructured":"Kn\u00fcppel L, Ishikawa Y, Aichler M, Heinzelmann K, Hatz R, Behr J, Walch A, B\u00e4chinger HP, Eickelberg O, Staab-Weijnitz CA (2017) A novel antifibrotic mechanism of Nintedanib and Pirfenidone. Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol 57:77\u201390. https:\/\/doi.org\/10.1165\/rcmb.2016-0217OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh P, Raychaudhuri S (2019) Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods 16:1289\u20131296. https:\/\/doi.org\/10.1038\/s41592-019-0619-0","journal-title":"Nat Methods"},{"key":"2176_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-241834","volume":"14","author":"F Kouzel Martinez","year":"2021","unstructured":"Kouzel Martinez F, Graffeo CS, Carlstrom LP, Link MJ (2021) Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment. BMJ Case Rep 14:e241834. https:\/\/doi.org\/10.1136\/bcr-2021-241834","journal-title":"BMJ Case Rep"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3171\/2020.3.JNS193230","volume":"134","author":"D Lewis","year":"2021","unstructured":"Lewis D, Donofrio CA, O\u2019Leary C, Li K, Zhu X, Williams R, Djoukhadar I, Agushi E, Hannan CJ, Stapleton E, Lloyd SK, Freeman SR, Wadeson A, Rutherford SA, Hammerbeck-Ward C, Evans DG, Jackson A, Pathmanaban ON, Roncaroli F, King AT, Coope DJ (2021) The microenvironment in sporadic and neurofibromatosis type II\u2013related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. J Neurosurg 134:1419\u20131429. https:\/\/doi.org\/10.3171\/2020.3.JNS193230","journal-title":"J Neurosurg"},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/neuonc\/noy177","volume":"21","author":"D Lewis","year":"2019","unstructured":"Lewis D, Roncaroli F, Agushi E, Mosses D, Williams R, Li K, Zhu X, Hinz R, Atkinson R, Wadeson A, Hulme S, Mayers H, Stapleton E, Lloyd SKL, Freeman SR, Rutherford SA, Hammerbeck-Ward C, Evans DG, Pathmanaban O, Jackson A, King AT, Coope DJ (2019) Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro Oncol 21:314\u2013325. https:\/\/doi.org\/10.1093\/neuonc\/noy177","journal-title":"Neuro Oncol"},{"key":"2176_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","volume":"109","author":"E Lou","year":"2012","unstructured":"Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS, Reardon DA (2012) Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series. J Neurooncol 109:63\u201370. https:\/\/doi.org\/10.1007\/s11060-012-0861-0","journal-title":"J Neurooncol"},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/S11060-019-03234-8","volume":"144","author":"VM Lu","year":"2019","unstructured":"Lu VM, Ravindran K, Graffeo CS, Perry A, Van Gompel JJ, Daniels DJ, Link MJ (2019) Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes. J Neurooncol 144:239\u2013248. https:\/\/doi.org\/10.1007\/S11060-019-03234-8","journal-title":"J Neurooncol"},{"key":"2176_CR29","unstructured":"MacDonald JW (2022) Affycoretools: Functions useful for those doing repetitive analyses with Affymetrix GeneChips (R package version 1.68.1.). Bioconductor"},{"key":"2176_CR30","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000174","author":"V Mart\u00ednez-Glez","year":"2007","unstructured":"Mart\u00ednez-Glez V, Franco-Hernandez C, Alvarez L, De Campos J, Isla A, Vaquero J, Lassaletta L, Casartelli C, Rey J (2007) Meningiomas and schwannomas: molecular subgroup classification found by expression arrays. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo_00000174","journal-title":"Int J Oncol"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MAO.0000000000001247","volume":"38","author":"ME Mercado-Pimentel","year":"2017","unstructured":"Mercado-Pimentel ME, Miller C, Rolph DN, Villalobos EF, Dunn AM, Mohan PM, Igarashi S, Liu X, Yrun-Duffy M, Patel NK, Read CM, Francis RH, Lane AI, Murugesh S, Jacob A (2017) Inhibiting p21-activated kinase induces cell death in vestibular schwannoma and meningioma via mitotic catastrophe. Otol Neurotol 38:139\u2013146. https:\/\/doi.org\/10.1097\/MAO.0000000000001247","journal-title":"Otol Neurotol"},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona RI, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, Boutros PC, Bader GD, de Carvalho DD, Kislinger T, Aldape K, Zadeh G (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597:119\u2013125. https:\/\/doi.org\/10.1038\/s41586-021-03850-3","journal-title":"Nature"},{"key":"2176_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","volume":"109","author":"L Nayak","year":"2012","unstructured":"Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109:187\u2013193. https:\/\/doi.org\/10.1007\/s11060-012-0886-4","journal-title":"J Neurooncol"},{"key":"2176_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/NMETH.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453. https:\/\/doi.org\/10.1038\/NMETH.3337","journal-title":"Nat Methods"},{"key":"2176_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.05.007","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner V-F, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, Huson SM, Wolkenstein P, Evans DG (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007","journal-title":"Genet Med"},{"key":"2176_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358\u2013367. https:\/\/doi.org\/10.1056\/NEJMoa0902579","journal-title":"N Engl J Med"},{"key":"2176_CR37","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, Bakker A, Fell G, Trippa L, Blakeley JO (2024) Brigatinib in NF2-related schwannomatosis with progressive tumors. N Engl J Med 390:2284\u20132294. https:\/\/doi.org\/10.1056\/NEJMoa2400985","journal-title":"N Engl J Med"},{"key":"2176_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/NOAJNL\/VDZ018","volume":"1","author":"DT Proctor","year":"2019","unstructured":"Proctor DT, Huang J, Lama S, Albakr A, Van Marle G, Sutherland GR (2019) Tumor-associated macrophage infiltration in meningioma. Neuro-Oncol Adv 1:1\u201310. https:\/\/doi.org\/10.1093\/NOAJNL\/VDZ018","journal-title":"Neuro-Oncol Adv"},{"key":"2176_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa153","author":"Y Ren","year":"2021","unstructured":"Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM (2021) New developments in neurofibromatosis type 2 and vestibular schwannoma. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaa153","journal-title":"Neuro-Oncol Adv"},{"key":"2176_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKV007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https:\/\/doi.org\/10.1093\/NAR\/GKV007","journal-title":"Nucleic Acids Res"},{"key":"2176_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","volume":"129","author":"KC Shih","year":"2016","unstructured":"Shih KC, Chowdhary S, Rosenblatt P, Weir AB, Shepard GC, Williams JT, Shastry M, Burris HA, Hainsworth JD (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129:281\u2013288. https:\/\/doi.org\/10.1007\/s11060-016-2172-3","journal-title":"J Neurooncol"},{"key":"2176_CR42","doi-asserted-by":"publisher","unstructured":"Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, Huson SM, Freeman SR, Lloyd S, Rutherford SA, King AT, Wallace AJ, Ramsden RT, Gareth D, Evans R Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. https:\/\/doi.org\/10.1136\/jmg.2010.085241","DOI":"10.1136\/jmg.2010.085241"},{"key":"2176_CR43","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1097\/MAO.0b013e3182956169","volume":"34","author":"SA Spear","year":"2013","unstructured":"Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB, Chang L-S (2013) Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma. Otol Neurotol 34:1519\u20131527. https:\/\/doi.org\/10.1097\/MAO.0b013e3182956169","journal-title":"Otol Neurotol"},{"key":"2176_CR44","doi-asserted-by":"crossref","unstructured":"Steen CB, Liu CL, Alizadeh AA, Newman AM (2020) Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. pp 135\u2013157","DOI":"10.1007\/978-1-0716-0301-7_7"},{"key":"2176_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/S11060-019-03388-5","volume":"146","author":"R Tamura","year":"2020","unstructured":"Tamura R, Morimoto Y, Sato M, Kuranari Y, Oishi Y, Kosugi K, Yoshida K, Toda M (2020) Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas. J Neurooncol 146:265\u2013273. https:\/\/doi.org\/10.1007\/S11060-019-03388-5","journal-title":"J Neurooncol"},{"key":"2176_CR46","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.3390\/ijms23105462","volume":"23","author":"R Tamura","year":"2022","unstructured":"Tamura R, Toda M (2022) A critical overview of targeted therapies for Vestibular Schwannoma. Int J Mol Sci 23:5462. https:\/\/doi.org\/10.3390\/ijms23105462","journal-title":"Int J Mol Sci"},{"key":"2176_CR47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s40478-023-01645-3","volume":"11","author":"Y Teranishi","year":"2023","unstructured":"Teranishi Y, Miyawaki S, Nakatochi M, Okano A, Ohara K, Hongo H, Ishigami D, Sakai Y, Shimada D, Takayanagi S, Ikemura M, Komura D, Katoh H, Mitsui J, Morishita S, Ushiku T, Ishikawa S, Nakatomi H, Saito N (2023) Meningiomas in patients with neurofibromatosis type 2 predominantly comprise \u2018immunogenic subtype\u2019 tumours characterised by macrophage infiltration. Acta Neuropathol Commun 11:156. https:\/\/doi.org\/10.1186\/s40478-023-01645-3","journal-title":"Acta Neuropathol Commun"},{"key":"2176_CR48","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/or.2014.3526","volume":"32","author":"M Torres-Martin","year":"2014","unstructured":"Torres-Martin M, Lassaletta L, Isla A, De Campos JM, Pinto GR, Burbano RR, Castresana JS, Melendez B, Rey JA (2014) Global expression profile in low grade meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 compared to their healthy tissue. Oncol Rep 32:2327\u20132334. https:\/\/doi.org\/10.3892\/or.2014.3526","journal-title":"Oncol Rep"},{"key":"2176_CR49","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/OR.2014.3526\/HTML","volume":"32","author":"M Torres-Martin","year":"2014","unstructured":"Torres-Martin M, Lassaletta L, Isla A, De Campos JM, Pinto GR, Burbano RR, Castresana JS, Melendez B, Rey JA (2014) Global expression profile in low grade meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 compared to their healthy tissue. Oncol Rep 32:2327\u20132334. https:\/\/doi.org\/10.3892\/OR.2014.3526\/HTML","journal-title":"Oncol Rep"},{"key":"2176_CR50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","volume":"34","author":"M de Vries","year":"2013","unstructured":"de Vries M, Briaire-de Bruijn I, Malessy MJA, de Bru\u00efne SFT, van der Mey AGL, Hogendoorn PCW (2013) Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 34:347\u2013352. https:\/\/doi.org\/10.1097\/MAO.0b013e31827c9fbf","journal-title":"Otol Neurotol"},{"key":"2176_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13059-017-1382-0\/FIGURES\/1","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P, Theis FJ (2018) SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19:1\u20135. https:\/\/doi.org\/10.1186\/S13059-017-1382-0\/FIGURES\/1","journal-title":"Genome Biol"},{"key":"2176_CR52","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","volume":"133","author":"MW Youngblood","year":"2020","unstructured":"Youngblood MW, Duran D, Montejo JD, Li C, Omay SB, \u00d6zduman K, Sheth AH, Zhao AY, Tyrtova E, Miyagishima DF, Fomchenko EI, Hong CS, Clark VE, Riche M, Peyre M, Boetto J, Sohrabi S, Koljaka S, Baranoski JF, Knight J, Zhu H, Pamir MN, Av\u015far T, Kilic T, Schramm J, Timmer M, Goldbrunner R, Gong Y, Bayri Y, Amankulor N, Hamilton RL, Bilguvar K, Tikhonova I, Tomak PR, Huttner A, Simon M, Krischek B, Kalamarides M, Erson-Omay EZ, Moliterno J, G\u00fcnel M (2020) Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 133:1345\u20131354. https:\/\/doi.org\/10.3171\/2019.8.JNS191266","journal-title":"J Neurosurg"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02176-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02176-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02176-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:16:14Z","timestamp":1766499374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-025-02176-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02176-9","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}